Journal of the American Pharmacists Association最新文献

{"title":"Evaluating the role of pharmacists in providing care with long-acting injectables for HIV and PrEP","authors":"Shreya Barde,&nbsp;Rebecca Lahrman,&nbsp;Jacquelyn Kissel,&nbsp;Teagan Vaughn,&nbsp;Alvin Choy,&nbsp;Jennifer Seifert,&nbsp;Junan Li,&nbsp;Laura E. Hall","doi":"10.1016/j.japh.2026.103149","DOIUrl":"10.1016/j.japh.2026.103149","url":null,"abstract":"<div><h3>Background</h3><div>Ending the HIV epidemic remains a global public health priority, with ongoing efforts to minimize infections by 2030. Pharmacists play a crucial role in managing HIV prevention (PrEP) with cabotegravir (CAB) and treatment with cabotegravir/rilpivirine (CAB/RPV) by optimizing antiretroviral (ARV) therapies and adherence. An Ohio-based not-for-profit organization with health care clinics and in-house pharmacies has implemented a pharmacist-led program managing long-acting injectable antiretrovirals (LAI-ARVs) using collaborative practice agreements (CPAs) with clinic providers. The innovative workflow addresses LAI-ARV implementation challenges and leverages pharmacist expertise to optimize patient care.</div></div><div><h3>Objectives</h3><div>The primary objective of this study is to evaluate the role of ambulatory care pharmacists in a LAI-ARV program by describing approval/denial to the program after primary care provider referral. The secondary objective is to quantify the ambulatory care pharmacist interventions during HIV treatment/PrEP LAI program Referral Review.</div></div><div><h3>Methods</h3><div>A CPA was developed at 5 clinic locations to implement a pharmacist-led LAI-ARV program for the treatment and prevention of HIV. Referral data were retrospectively reviewed to assess approval or denial of potential injectable candidates and to describe pharmacist interventions.</div></div><div><h3>Results</h3><div>Out of the 1103 referrals reviewed, 893 were approved and 210 were denied. CAB/RPV referrals had more denials due to safety and efficacy concerns. Of the 893 approved referrals, 264 required at least one clinical intervention to address logistic, safety, and efficacy considerations before initiation of LAI-ARV. Pharmacist interventions often address safety concerns such as hepatitis B virus risk, drug interactions, and risk of in adherence to appointments.</div></div><div><h3>Conclusion</h3><div>This study highlights the impact of pharmacist-led processes in optimizing LAI-ARV therapy through patient-specific evaluation and clinical interventions. Pharmacist involvement ensures appropriate candidate selection, safe therapy implementation, and supports the broader public health efforts to reduce HIV transmission and end the HIV epidemic.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103149"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148045425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of clinical trials on deprescribing: A comprehensive analysis of the ClinicalTrials.gov database","authors":"Yu Wang,&nbsp;Yingying Gong,&nbsp;Xiangbin Zhong,&nbsp;Chen Li,&nbsp;Hua Yin,&nbsp;Wen He,&nbsp;Hua Hong,&nbsp;Gang Yuan,&nbsp;Kemin Yan","doi":"10.1016/j.japh.2026.103150","DOIUrl":"10.1016/j.japh.2026.103150","url":null,"abstract":"<div><h3>Background</h3><div>Understanding the current features of deprescribing clinical trials is crucial for improving trial designs and identifying research gaps.</div></div><div><h3>Objective</h3><div>This study aims to provide a comprehensive overview of deprescribing trials registered in <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>.</div></div><div><h3>Methods</h3><div>We searched the <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> database for deprescribing clinical trials and evaluated the characteristics of these relevant studies. For the primary completed trials, we also searched PubMed and Google Scholar to confirm their publication statuses.</div></div><div><h3>Results</h3><div>We identified 125 deprescribing trials for analysis. Only 39.2% were completed, 88.0% were interventional trials, 56.0% enrolled only the elderly, 70.4% were single-center clinical trials, and 35.2% were sited in the United States. The number of interventional trials registered before patient recruitment from 2021 to 2025 was higher than that from 2012 to 2020 (<em>P</em> &lt; 0.05). Compared with unpublished clinical trials, published ones had larger sample sizes, more parallel intervention models, and more registered after recruitment (all <em>P</em> &lt; 0.05). The cumulative publication rate within 5 years after the completion of primary trials was 60.7%. The journal with the highest impact factor (IF) for publication was JAMA Internal Medicine (Q1, IF 23.3), and the one with the largest number of publications was BMC Geriatrics (Q2, IF 3.8).</div></div><div><h3>Conclusion</h3><div>Our study showed that deprescribing trials were mostly large-scale and single-center studies, mainly carried out in developed countries, and most of them were incomplete, lacking results and publications. Therefore, it is necessary to carry out such trials in developing countries, and to pay more attention to improving their completion rates, as well as promoting the publication and dissemination of their results.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103150"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148045436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient response to changes in available Medicare Part D coverage plans: A case study","authors":"Tyler S. Dougherty,&nbsp;Krishna Mahida,&nbsp;Elizabeth Nguyen","doi":"10.1016/j.japh.2026.103148","DOIUrl":"10.1016/j.japh.2026.103148","url":null,"abstract":"<div><h3>Background</h3><div>Medicare Part D provides prescription coverage for Medicare beneficiaries. Community pharmacies dispense a substantial share of Part D prescriptions but face growing financial strain because pharmacy benefit manager reimbursement rates can be less than acquisition and operating costs. Community pharmacies can choose not to accept an insurance plan, though this has implications for patient access and pharmacy revenue.</div></div><div><h3>Objective</h3><div>The purpose of this study is to determine patient behavior changes in relation to a community pharmacy's decision to no longer accept certain Medicare Part D plans.</div></div><div><h3>Methods</h3><div>A retrospective analysis was conducted to evaluate patterns after a notice letter was sent to beneficiaries specifying which plans will be accepted and not accepted in 2026. The data focused on Medicare Part D plans from 2025 to 2026 and further broken down by accepted or nonaccepted plans. The study evaluated participants continuing to purchase prescriptions at the community pharmacy despite having a nonaccepted Medicare Part D plan.</div></div><div><h3>Results</h3><div>A total of 119 participants were included in the analysis, and 61 participants (51.26%) switched their Medicare Part D plan while 58 (48.74%) remained on the same plan from 2025. However, 80 (67.23%) continued to use the community pharmacy, with 10 patients having pre-existing accepted secondary plans, and 12 continued to obtain prescriptions at the pharmacy despite their Medicare Part D plan not being accepted. Twenty-three (19.33%) patients who did not have an accepted plan in 2026 transferred prescriptions to a different pharmacy.</div></div><div><h3>Conclusion</h3><div>This study evaluated Medicare Part D plan switching in relation to a community pharmacy's decision to no longer accept certain Medicare Part D plans during open enrollment. Medicare Part D plan switch rates were higher than national estimates. Clear communication may decrease loss of patients when a community pharmacy chooses to no longer accept a Medicare Part D plan.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103148"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148020521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from a pilot interprofessional preceptor development program using the Habits of Preceptors platform","authors":"Elizabeth K. Pogge,&nbsp;Kellie J. Goodlet,&nbsp;Erin C. Raney,&nbsp;Suzanne Larson,&nbsp;Lindsay E. Davis","doi":"10.1016/j.japh.2026.103153","DOIUrl":"10.1016/j.japh.2026.103153","url":null,"abstract":"<div><h3>Background</h3><div>Training under the guidance of preceptors is a foundational component of health care education. Despite this vital role, most practicing clinicians receive little formal preparation for teaching. Clinicians who precept seek development opportunities that are pragmatic, expand networks, and are flexible to support work-life integration. However, availability of and access to such training is often hindered by cost, fragmentation, and lack of structured frameworks for self-reflection and application to practice.</div></div><div><h3>Objective</h3><div>To explore satisfaction and perceived professional impact associated with participation in the pilot offering of the Habits of Preceptors (HOP) Academy 101 Foundations Course for Clinician Educators.</div></div><div><h3>Methods</h3><div>The HOP Academy 101 Foundations Course was delivered as a 6-month, asynchronous, interprofessional pilot program incorporating curated educational content mapped to the 11 habits of the HOP Framework with concurrent guided self-reflection and peer discussion activities. Following course completion, volunteers participated in semistructured interviews.</div></div><div><h3>Results</h3><div>Twenty-four interprofessional clinician educators were invited to participate in the pilot program. Of these, 18 engaged in at least 1 course activity and 6 participated in an interview. Interviewees reported overall high satisfaction with the program and highlighted the practical applicability of the readings, resources, and near peer engagement. Targeted areas of personal growth included feedback practices, professional identity as clinician educators, and leadership capacity. Suggested program improvements included streamlining access across the two-learning platforms, shortening the program timeline, and increasing opportunities for peer and faculty interaction.</div></div><div><h3>Conclusion</h3><div>Findings from this pilot suggest that structured, asynchronous preceptor development that incorporates peer dialog, guided reflection, and individualized learning is valued by practicing clinicians. Participants reported self-perceived positive impact on precepting confidence and practices, as well as strengthening professional identity. This type of approach may address persistent gaps in traditional preceptor continuing education.</div></div>","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103153"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148160279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"160 Characteristics and Glycemic Outcomes of Insulin Naive Adults with Type 2 Diabetes Using a Fixed-Dose Regimen of Weekly Insulin Efsitora in QWINT-1","authors":"V. Patel,&nbsp;A. Knights,&nbsp;M. Davidson","doi":"10.1016/j.japh.2026.103206","DOIUrl":"10.1016/j.japh.2026.103206","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103206"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148634147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"128 From Options to Enrollment: What Drives Pharmacy School Choice for Students with Multiple Admissions Offers?","authors":"W. Yebuah,&nbsp;K. Goodlet,&nbsp;M. Heberling,&nbsp;N. Christofferson","doi":"10.1016/j.japh.2026.103178","DOIUrl":"10.1016/j.japh.2026.103178","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103178"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148634322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actions of the 2026 American Pharmacists Association House of Delegates, Los Angeles, CA, March 27–30, 2026","authors":"","doi":"10.1016/j.japh.2026.103133","DOIUrl":"10.1016/j.japh.2026.103133","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103133"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148634566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"133 Impact of Near-Peer Teaching on Entrustable Professional Activities","authors":"O. Ketana,&nbsp;C. Duong,&nbsp;S. Kourtakis","doi":"10.1016/j.japh.2026.103183","DOIUrl":"10.1016/j.japh.2026.103183","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103183"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148640452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"106 Drug Optimization for Eczema Treatment","authors":"M. Diep,&nbsp;T.J. On,&nbsp;J. Totonchy","doi":"10.1016/j.japh.2026.103161","DOIUrl":"10.1016/j.japh.2026.103161","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103161"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148641210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover","authors":"","doi":"10.1016/S1544-3191(26)00463-2","DOIUrl":"10.1016/S1544-3191(26)00463-2","url":null,"abstract":"","PeriodicalId":50015,"journal":{"name":"Journal of the American Pharmacists Association","volume":"66 4","pages":"Article 103478"},"PeriodicalIF":2.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148641227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}